GANIYAT ADEYEMO: Open Payments
NPI 1588113351 · SEVERN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$543 in 25 payments from 9 companies in 2025. Trend: 2023 $691 · 2024 $866 · 2025 $543
Food & beverage: $543
| Company | Payments | Amount |
|---|---|---|
| Tris Pharma Inc | 7 | $112 |
| ABBVIE INC. | 4 | $106 |
| Neurocrine BioSciences, Inc. | 4 | $104 |
| Vanda Pharmaceuticals Inc. | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
| Corium, LLC | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, INGREZZA, Dyanavel XR, HETLIOZ, COBENFY, Azstarys, AUSTEDO XR, FANAPT.
Industry payments across MD — which companies pay providers there.
